Trial Profile
A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 May 2019
Price :
$35
*
At a glance
- Drugs Poractant alfa (Primary)
- Indications Respiratory distress syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 09 Oct 2017 Status changed from not yet recruiting to recruiting.
- 23 Mar 2017 New trial record